Clinical trial · Observational
Role of Positron Emission Tomography/ Computed Tomography (PET/CT) and in Bone Metastases.
Role of Positron Emission Tomography/Computed Tomography in Detecting Bone Metastases in Cancer Patients.
NCT04080271CI-TRIAL-00059421PET/CTcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to detect bone metastases by PET/CT examination in cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Metastases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-FDG PET/CT | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- description of bone metastases detected by PET/CT in cancer patients.
- timeFrame
- one year
- description
- Analysis of number, type and SUVmax of metastatic bony lesions detected by PET/CT in cancer patients.
- measure
- compare diagnostic performance of PET/CT, planar bone scintigraphy and SPECT/CT in detecting bone metastases
- timeFrame
- one year
- description
- compare sensitivity, specificity, PPV,NPV and accuracy
Secondary outcomes (1)
- measure
- risk benefit of PET/CT examination in cancer patients
- timeFrame
- one year
- description
- To evaluate risk benefit of PET/CT examination in cancer patients suspected to have bone metastasis.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * patients diagnosed with different types of malignant tumor, suspected or diagnosed to have bone metastases and will do PET/CT examination * patients diagnosed with different types of malignant tumor, with accidently discovered bone metastases during PET/CT examination. * patients conscious to provide informed consent. Exclusion Criteria: * pregnant women. * patients with blood sugar \> 200 mg/dL. * patients unable to sleep in a fixed position for 20 minutes. * severely ill patients who aren't capable of complying with study procedures or comatose patients.
References
Publications (6)
- BACKGROUNDSuva LJ, Washam C, Nicholas RW, Griffin RJ. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 2011 Apr;7(4):208-18. doi: 10.1038/nrendo.2010.227. Epub 2011 Jan 4. PMID 21200394
- BACKGROUNDChoi J, Raghavan M. Diagnostic imaging and image-guided therapy of skeletal metastases. Cancer Control. 2012 Apr;19(2):102-12. doi: 10.1177/107327481201900204. PMID 22487972
- BACKGROUNDColeman R, Body JJ, Aapro M, Hadji P, Herrstedt J; ESMO Guidelines Working Group. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014 Sep;25 Suppl 3:iii124-37. doi: 10.1093/annonc/mdu103. Epub 2014 Apr 29. PMID 24782453
- BACKGROUNDCrawford ED, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger ER, Keane TE, Sieber P, Shore ND, Petrylak DP; Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Group. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 2014 Mar;83(3):664-9. doi: 10.1016/j.urology.2013.10.026. Epub 2014 Jan 8. PMID 24411213
- BACKGROUNDRosenthal DI. Radiologic diagnosis of bone metastases. Cancer. 1997 Oct 15;80(8 Suppl):1595-607. doi: 10.1002/(sici)1097-0142(19971015)80:8+3.3.co;2-z. PMID 9362427
- BACKGROUNDNational Comprehensive Cancer Network (NCCN) Breast Cancer NCCN Practice Guidelines in Oncology. Fort Washington, PA:NCCN. 2014. Ver. 2.